Open in interactive viewer → charts, metric popovers & call review

Superior Group Finally Buys Its Way Into the Philippines — and Stops Talking About Slow Decisions

SGC closes a three-quarter-old promise with a $27M offshore BPO deal, posts a second Healthcare Apparel write-down, and quietly retires its favorite excuse.
SGC · Earnings Call · 2026-11-09

The deal that was promised for three straight calls

For most of 2026, Superior Group of Companies has been telling investors it wanted to be in the Philippines and that it would get there one way or another. On the March call, Michael Benstock was explicit: “either we will have an acquisition done this year or we will find ourselves doing a start-up of a call center in the Philippines” — Michael Benstock, Chief Executive Officer · 2026-08-04. Two quarters later, the Select VoiceCom acquisition is a fact — roughly $27 million in cash up front plus a one-year earnout, at what CFO Mike Koempel pegged as “a multiple of about 5x estimated earnings” — Michael Koempel, President and Chief Financial Officer · 2026-11-09 on about $20 million of annual revenue. The strategic logic is straightforward and, unusually for a small-cap bolt-on, genuinely additive. Dominic Leide framed it as a menu expansion: “We've built a strong nearshore platform, and what Select VoiceCom adds is an established offshore operation in the Philippines” — Dominic Leide, President of the Contact Center segment · 2026-11-09 — nearshore, onshore and offshore, or blended "right-shoring." Critically it brings healthcare vertical expertise and, per Leide, the ability to hire Filipino registered nurses and physical therapists, which gives the sales team something to sell into new logos rather than just defend existing ones. Segment addressable market is the phrase management reached for, and it is the right one: this is a geography-and-capability land grab, not a share-shift inside El Salvador. The market's response was a shrug. The stock sits 10.7% below its August 6 peak of $14.13 and is essentially flat over the last seventeen weeks. At a $201 million market cap, SGC is small enough that a $27 million deal is real, and the tape is not yet voting on it.

A two-speed portfolio, with Healthcare as the ballast dragging

Q3 was a clean demonstration of what SGC looks like when its two healthy segments are allowed to run. Revenue rose 5% to $146 million — an acceleration from Q2's 3% — with Branded Products up 8% to $92 million and Contact Centers up 7% to $24 million. Those two grew EBITDA 31% and 22% respectively. Branded Products gross margin expanded 160 basis points on favorable customer and pricing mix. Then Healthcare Apparel took it all back. Segment revenue fell 3%, gross margin dropped 580 basis points, and segment EBITDA came in about $3.7 million below the prior year, driven by “a $4 million incremental inventory write-down in connection with further streamlining the product assortment, partially offset by $1.8 million of tariff refunds” — Michael Koempel, President and Chief Financial Officer · 2026-11-09. Consolidated gross margin held flat at 38% only because Branded Products won back in basis points what Healthcare gave away. Gross margin: 38.0%, flat year-over-year, against a 39.2% peak set in 2024Q3 This is the second consecutive quarter of inventory write-down in the same segment, and the language has not gotten any more comfortable. In August, Koempel sketched a path: “I would anticipate still some margin pressure on a year-over-year basis and then begin to see improvements in 2027.” — Michael Koempel, President and Chief Financial Officer · 2026-08-04 On this call the horizon moved out a touch — “we'd still expect there to be margin pressure heading into the first half of next year” — Michael Koempel, President and Chief Financial Officer · 2026-11-09 — and the mix shifted from write-downs to discounting, which is a slower, softer form of the same pain. The margin pressure keyword, which ranked near the top of SGC's own keyword trajectory last quarter, is now a structural feature rather than a footnote. Healthcare Apparel business has become the single largest swing factor in the equity story.

The quiet retreat from "slow decision making"

The most telling change in this transcript is an absence. For at least three consecutive quarters, SGC's calls were dominated by customer hesitancy — decision making ranked second in the company's own keyword trajectory in 2026Q3, and words like "elongated," "hesitancy" and "slow" recurred as explanation for why pipelines would not convert. On this call, the theme is essentially gone. Branded Products is described as its fourth consecutive strong quarter, Contact Centers is growing, and the friction has moved from demand to execution. Branded Products' competitive framing has hardened usefully too. Koempel on the tariff backdrop and smaller competitors: “certainly in times of tariffs and rising costs, we are certainly operate from a position of strength versus smaller competitors” — Michael Koempel, President and Chief Financial Officer · 2026-11-09. That echoes what Jake Himelstein said two calls back — “we're gaining share organically” — Jake Himelstein, President of Branded Products segment · 2026-08-04 — but now with a balance sheet behind it and a newly-added Chief Revenue Officer and head of marketing to press the advantage. Koempel also let slip the ambition size: “we want to keep the momentum going as well as grow even larger as we approach our long-term goal of hitting $1 billion” — Michael Koempel, President and Chief Financial Officer · 2026-11-09. Branded Products runs at roughly a $370 million annualized pace, so this is a multi-year framing, not a forecast. One place management got softer, not sharper, is the Healthcare credit charge. What SGC once called a customer bankruptcy is now described as "the change in a customer's financial position," and the $1 million hit was only pried out of Koempel after an explicit follow-up. The euphemism is worth flagging.

Tariffs, cash, and a valuation that refuses to re-rate

SGC is riding one genuinely global current: the tariff refund wave. Global keyword data shows tariff-refund themes among the strongest price movers over 360 and 90 days, with consumer-goods names like LEVI, SWK and KMB leading. SGC's $1.8 million of refunds is small but it is real cash, and it lands in a business that badly needs it. What is far more important is the balance sheet turn. Year-to-date operating cash flow of $31 million against $1 million a year earlier, average debt outstanding down $25 million, and quarterly net interest expense down to just over $800,000 from $1.4 million. The 10-Q shape confirms the direction: Free cash flow less stock comp: $6M in the June quarter, up 202% year-over-year. Even so, the leverage picture is not yet comfortable — effective net cash of -$59M and interest coverage of 1.2x leave little room for a misstep in Healthcare Apparel. Which makes the valuation the real puzzle. Price to revenue: 0.4x, down from 1.5x in 2017Q4. The market is paying almost nothing for the recovery. Full-year guidance was tightened to $578–585 million of revenue and $0.60–$0.66 of adjusted EPS — 43% EPS growth at the high end over 2025's $0.46.

We have no idea what next year is going to look like. Anybody who says they know what next year is going to look like, don't believe them... We're hoping that nothing gets done in Washington for the next couple of years, and that's pretty much what we're banking on.

It is a refreshingly honest answer, and it captures the whole problem: SGC is executing on the things it controls — the Philippines deal, branded share gains, cash conversion — while the re-rating depends on the one segment where new leadership is still discounting its way through an assortment reset. The offshore acquisition is now done. The Healthcare turnaround is the only promise still outstanding.